POS0055 TNF-α REGULATION OF mir-29b EXPRESSION IN CD14+PBMs AND ITS RELEASE OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ARTHRITIS

Background It was found that the expression of mir-29b significantly up-regulated in PBMs, and we tried to clarify TNF- α The production proinflammatory cytokines increased by inducing overexpression CD14 +PBMs patients with rheumatoid arthritis (RA), using TNF-α urapy reverse regulate mir-29b, carry out relevant experiments verify our scientific research hypothesis. Objectives By observing RA treated experimenperipheral blood mononuclear cells (CD14+PBMs) releases pro-inflammatory cytokines. Methods (1) Cell experiment: PBM from were collected extracted for CD14+ cell labeling. Different doses c500 ng/ml) used intervention. Meanwhile, analyzed rt-qpcr at level TNF-α100 ng/ml different periods time (0,6,12,24h). In addition, supernatant culture human IL-1α, IL-1β, TNFα, IL-6, IFN-α IL-8 measured a V-plex cytokine 30-plex kit. (2)Grouping experiment clinical intervention: 21 diagnosis 15 healthy volunteers divided into three groups. inhibitor group: (n=15); IL-6 monoclonal antibody tocilizumab (n=6); Control (n=15) as normal controls. PBMc group 6 months, control group, respectively, observe difference Mir-29b CD14+PBMs Results miR-29b dose-dependent time-dependent incubation TNF-α, there significant (P < 0.05). Compared also led an increase levels wide range chemokines (including IL-8) reduced compared Totuzumab (P<0.05). Conclusion inflammatory factors can induce patients, then producing large number cytokines, which aggravate inflammation mechanism RA. inhibitors may partially reduce response through TNF-α/CD14+PBMs/ signaling pathway. Therefore, more attention should be paid practice, accurately indicate state immune disease provide basis accurate judgment prognosis course immunotherapy, well optimization immunotherapy programs. References [1]Long L, Yu P, Liu Y, et al. Upregulated microRNA-155 peripheral fibroblast-like synoviocytes arthritis. Clin Dev Immunol. 2013;2013:296139. Disclosure Interests None declared